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I N T RO D U C T ION
N-nitrosodimethylamine (NDMA), a probable human carcinogen, was discovered decades ago, although elevated levels
in several widely used drugs were detected only recently.
Several medications that are now known to contain NDMA
have remained available, whereas ranitidine has been completely withdrawn from the market. In the following paper,
we discuss the overview of events that led to the withdrawal
of ranitidine and compare evidence and subsequent regulatory response of other medications also containing NDMA.
Our prior commentary detailed what is known about N-
nitrosodimethylamine (NDMA), initial US Food and Drug
Administration (FDA) evaluation of affected ranitidine products, and limits in existing data to assess best practices for
NDMA detection in drug products.1 Briefly, NDMA is considered a probable carcinogen by the International Agency for
Research on Cancer,2 given that several animal studies have
demonstrated adverse effects with chronic exposure to NDMA,
including tumors of the liver, lungs, and stomach. NDMA
metabolism in the liver results in the formation of methyldiazonium, a molecule that readily chelates to DNA and other
macromolecules with cytochrome P450 families CYP2E and

CYP2A believed to be key mediators in the formation of this
metabolite. In vitro metabolism data from human liver samples
suggests that formation of the methyldiazonium metabolite is
comparable to that of laboratory animals, and thus NDMA
may also be a procarcinogen in humans. Although human
exposure to N-nitrosamine is a common occurrence from numerous sources, including manufacturing byproducts, food and
beverages, and even drinking water, several medications have
recently been reported to contain NDMA in quantities greater
than the acceptable daily intake (ADI) limit set by the FDA.
NDMA presence above the ADI in marketed drugs was
first reported in 2018 when an American manufacturer of
valsartan, an angiotensin II receptor blocker (ARB) frequently prescribed to treat hypertension and heart failure,3
alerted the FDA that NDMA had been detected. The FDA
confirmed levels ranging from below the ADI of 0.096 μg up
to 20.19 μg per tablet4 (Table 1). Batches of ARBs losartan
and irbesartan were also affected, resulting in nearly 40 recalls, although unaffected lots remained on the market. The
impurity was thought to be linked to manufacturing changes
in 2014, wherein sodium nitrite integral to synthesis of many
ARBs containing a tetrazole ring, reacted with amines resulting in formation of NDMA. Neither regulators nor industry
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TABLE 1

COMMENTARY

Comparison of medications known to contain NDMA

Medication

Highest NDMA
level, µg, per dose

Maximum daily
dosing, mg

Ranitidine

0.86 per 300 mg

Nizatidine

0.02 per 150 mg

Cause of NDMA

FDA response

300

Undetermined but increases with application
of heat

Complete market withdrawal

300

Undetermined

Voluntary recalls of affected products

Irbesartan

Unpublished

300

Manufacturing process

Voluntary recalls of affected products

Losartan

Unpublished

100

Manufacturing process

Voluntary recalls of affected products

Valsartan

20.19 per 320 mg

320

Manufacturing process

Voluntary recalls of affected products

Metformina

0.19 per 500 mg

2000

Undetermined

Voluntary recalls of affected products

Note: Comparison of NDMA levels of affected medications and cause of impurity as reported by the FDA as well as agency response.4,6,8 Typical maximum daily
dosing of oral products is reported.
Abbreviations: FDA, US Food and Drug Administration; NDMA, N-nitrosodimethylamine.

a

Extended-release formation.

had anticipated increased risk of NDMA formation in ARBs,
thus testing for NDMA was not regular practice.
In September 2019, a new petition alerted the FDA to elevated NDMA levels in ranitidine,5 an H2-receptor antagonist
(H2RA), prompting a voluntary recall. Although the FDA reported NDMA concentrations ninefold higher than the ADI,
the levels were much lower than those reported by the petitioner possibly due to different laboratory practices and higher
temperatures used in detection methods, prompting the FDA
to communicate specific testing guidance to manufacturers.
Although the FDA continues to determine root causes, the
agency has confirmed NDMA formation in ranitidine is not
purely secondary to manufacturing processes,6 unlike affected
ARBs. Suppositions about the exact mechanism remain, and
the petitioner has highlighted the potential for instability of
ranitidine, which contains both a nitrite and a dimethylamine
group.5 Other nitrites introduced into the gastrointestinal tract
have also been considered possible biological sources reacting to form NDMA in ranitidine, but the FDA strongly rejects
this theory, as the agency’s simulated gastric and intestinal
fluid testing results did not yield elevated levels.
Several countries have reported NDMA above the ADI
limit in nizatidine products, an H2RA structurally similar
to ranitidine. The Korea Ministry of Food and Drug Safety
suspended manufacturing and prescription of 13 nizatidine
products following detection of NDMA at or above the same
threshold used as the FDA.7 Initial testing of four nizatidine
products conducted by the FDA were found to be below the
ADI. Voluntary recalls of nizatidine in the United States
have been initiated, however, the levels in the recalled products have not been published. The FDA has not publicly announced plans for further situational testing of NDMA in
nizatidine, such as shelf stability or exposure to heat.
Recently, NDMA was found in international metformin
products, prompting FDA evaluation. Initial FDA testing of
metformin, the medication commonly used in the treatment
for type 2 diabetes mellitus, revealed either nondetectable or

reassuring levels.8 In March 2020, the same petitioner that reported NDMA in ranitidine released analysis of 38 metformin
batches. Sixteen of the batches from 11 companies exceeded
ADI limits when common daily treatment dose was factored,
and variability in NDMA levels among batches even within
a single company was described.9 By May, the agency announced voluntary recalls of metformin extended-release formulations. Inconsistency between lots was confirmed, but the
FDA reported levels were again generally lower than recorded
by the petitioner. The agency stated the source of NDMA remains unknown and has not been detected in immediate release metformin or the API. The petitioner posits the NDMA
may be primarily due to contamination during manufacturing
as opposed to instability of the molecule. Voluntary recalls
have continued with unaffected lots remaining on the market.
With ongoing evaluation of the potentially affected drugs,
in April 2020, the FDA requested immediate withdrawal
of all ranitidine products, citing that NDMA levels could
increase when stored at high temperatures, such as might
occur during distribution, handling, or even normal storage
conditions. The European Medicines Agency shortly thereafter, recommended suspending all ranitidine products in the
European Union. Informing the decision was another petition
to the agency claiming ranitidine has limited shelf-life stability, and progressively accumulates NDMA at elevated temperatures (Figure 1).10 Evaluations determined that NDMA
levels could be acceptable at the manufacturing site but were
at risk of increasing by the time of consumption. The highest NDMA value remained well under the maximum amount
found in valsartan doses, but the small study set of ranitidine
products continued to produce increasing levels of NDMA
through termination of the experiment at 14 days.
The FDA recommended market withdrawal of ranitidine
reiterates the need to tailor response to each affected medication’s specific characteristics, not solely basing actions on
highest potential NDMA levels. Estimated treatment time-
courses, benefits of medication continuation versus risks
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F I G U R E 1 Preliminary ranitidine stability study as reported
by Emery Pharma. Preliminary stability study with United States
Pharmacopeial Convention (USP) ranitidine standard at 25°C, USP
ranitidine standard at 70°C, and ranitidine (Zantac 150 Cool Mint), at
70°C. N-nitrosodimethylamine (NDMA) analysis performed via liquid
chromatography tandem mass spectrometry (vide infra), and quantified
based on a calibration curve generated using an NDMA reference
standard. Dotted line approximately indicates the daily intake limit
of 96 ng for NDMA. Used by permission of Emery Pharma.10 The
generic of "Zantac" is ranitidine

of exposure, availability of alternative medication options,
source of impurity, assumed duration for which medications
have been affected, and known risk of carcinogenicity are
considered. Treatment with metformin or ARBs is typically
chronic, whereas H2RA treatment courses are generally recommended to be short term. Risks of untreated chronic hypertension and hyperglycemia are well-established, so a higher
hypothetical risk of cancer secondary to NDMA might be tolerated, and studies suggest metformin use may be associated
with statistically significant reductions in the risk of cancer
and cancer-related mortality.11 Risks associated with inadequate treatment of gastroesophageal reflux disease include
esophagitis, esophageal stricture, esophageal ulceration,
Barrett’s esophagus, esophageal dysplasia, and esophageal
adenocarcinoma, but there are well-known alternative treatment options, such as other structurally dissimilar H2RAs
famotidine and cimetidine and proton pump inhibitors. When
the source of NDMA is considered among the affected drugs,
the regulatory actions taken toward ranitidine clarifies the
more extensive actions. With proper oversight and testing,
an aberrant manufacturing process might be remedied, but if
the source is due to an inherently unstable molecule, such as
has been proposed for ranitidine, then proper manufacturing
protocols may not mitigate the risks of NDMA formation.
Additionally, changes in the manufacturing of ARBs argues
for a more recent presence of NDMA, whereas ranitidine
may always have had the potential to develop NDMA.
Epidemiological studies designed to inform true risk due
to long-term NDMA exposure from specific medications are
lacking. Although studies evaluating long-term valsartan risk
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are not available, a secondary analysis of a Danish cohort revealed no increase in short-term cancer risk for users of likely
affected products.12 With regard to ranitidine, after about 4
decades of usage, and millions of doses prescribed and purchased over the counter, a clear adverse signal with regard to
malignancy has not been observed. The few studies evaluating risk of cancer from ranitidine are underpowered, focus on
few specific cancers, lack appropriate case definitions, and/
or appropriate control populations as well as long-term follow-up, and were uninformed about potential NDMA presence. A large database of millions of H2RA users is being
investigated with early results reporting no increased risk of
various cancers in users of ranitidine compared with structurally dissimilar famotidine.13 However, early indication is
that the dataset does not differentiate long-term versus short-
term use. Population-based adverse event reviews and cancer
outcomes using pharmacy databases contained within hospital systems, health maintenance organizations, preferred
provider organizations, and managed care plans are critically
needed to provide epidemiological evidence to support or
disprove an association of increased cancer risk of affected
medications.
Additional examination of sources of NDMA production
is imperative, and manufacturers and regulators should have
a high index of suspicion given NDMA may result from production processes, storage processes, and possibly from endogenous processes. The establishment of uniform analytic
methodologies leading to reproducible results under a robust
number of conditions is essential. True exposure to NDMA
in vivo following ranitidine use would be informative particularly should other drugs be concerning for similar unstable
structures. Further analysis of NDMA ADI limits is warranted, particularly considering higher ADIs for treatment
courses traditionally lasting less than 70 years of daily use.
With current knowledge gaps, it is unclear if possible preventative and corrective actions may allow the return of ranitidine to the market. Considerations could include requiring
temperature indicator labels, temperature-controlled shipping
and storage, labels warning about the risk of carcinogenic
byproducts at high temperatures, dispersion by prescription
only, addition of reducing agents, and recommendations on
maximum length of treatment course.
Although the FDA continues to develop proactive industry guidance to be implemented so that all drugs can have
a standardized NDMA risk assessment, continued transparency is vital especially given discrepancies in NDMA
levels among laboratories. Drafting a singular regulatory response to medications affected by NDMA is unlikely given
the unique characteristics of each affected medication.
Ranitidine’s potential for elevated NDMA levels during
storage required its withdrawal from the market, and, in the
meantime, we will have to patiently await long-term epidemiological studies.
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